Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis

Jean Louis Vincent; Herbert Spapen; Jan Bakker; Nigel R. Webster; Lloyd Curtis

doi:10.1097/00003246-200003000-00006

Back

Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis

Article 2000 en

Abstract

1 min read

Treatment of sepsis with the platelet-activating factor antagonist BB-882 offers no advantage over placebo on survival, hemodynamic status, respiratory function, or organ failure scores.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article1997

TREATMENT WITH A PLATELET-ACTIVATING FACTOR ANTAGONIST HAS LITTLE PROTECTIVE EFFECTS DURING ENDOTOXIC SHOCK IN THE DOG

Herbert Spapen, Haibo Zhang, Virginie Verhaeghe, Peter Rogiers, Anna Cabral, Jean Louis Vincent

Article2000

A Double-Blind Placebo-Controlled Study of an Infusion of Lexipafant (Platelet-Activating Factor Receptor Antagonist) in Patients with Severe Sepsis

Yupin Suputtamongkol, Sunanta Intaranongpai, Michael D. Smith, Brian Angus, Wipada Chaowagul, Chairat Permpikul, J. A. Simpson, Amorn Leelarasamee, Lloyd Curtis, Sir Nicholas White

Antimicrobial Agents and Chemotherapy

Article1995

Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma.

L.M. Kuitert, Robert Angus, Neil Barnes, Peter J Barnes, M F Bone, Kian Fan Chung, A J Fairfax, T W Higenbotham, Brian O’Connor, B Piotrowska

Article1997

Effects of a Potent Platelet-activating Factor Antagonist, SR27417A, on Allergen-induced Asthmatic Responses

David J. Evans, Peter J Barnes, M Cluzel, Brian O’Connor

Article1993

Inhibition of Platelet-activating Factor-induced Bronchoconstriction by the Leukotriene D<sub>4</sub>Receptor Antagonist ICI 204,219

Joseph C. Kidney, S M Ridge, Kian Fan Chung, Peter J Barnes